Barinthus Biotherapeutics

BRNS

United Kingdom· Est. 2021

barinthusbio.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

BRNS · Stock Price

USD 0.67-0.20 (-22.72%)

Market Cap: $27.8M

Historical price data

Market Cap: $27.8MPipeline: 11 drugsFounded: 2021HQ: United Kingdom

Sector Ranking#64 in Immunotherapy / Immuno-Oncology #75 in Cell & Gene Therapy

Overview

Barinthus Biotherapeutics is a UK-based, NASDAQ-listed biotech (BRNS) focused on developing novel immunotherapies for immunology and inflammatory (I&I) indications. The company's strategy centers on its two core technology platforms—the proprietary SNAP nanoparticle system and the established ChAdOx/MVA viral vectors—to 'guide' antigen-specific T cell responses. Recent clinical achievements include positive Phase 1b/2a data for its chronic hepatitis B candidate, VTP-300, showing sustained antigen reduction, and a favorable tolerability profile for its HPV candidate, VTP-200. Barinthus aims to translate its strong academic heritage into differentiated clinical assets in areas of high unmet need.

Immunology & Inflammatory DiseasesInfectious Diseases

Technology Platform

A dual-platform approach featuring the proprietary SNAP (Self-assembling Nanoparticle) system for precise antigen delivery and immune modulation, combined with clinically validated viral vector platforms (ChAdOx and MVA) for potent T cell induction.

Pipeline

11 drugs in pipeline

Drug	Indication	Stage
MVA-NP+M1 + Saline	Influenza	Phase 2
ChAdOx1-HBV + MVA-HBV + Nivolumab	Chronic Hepatitis B	Phase 2
Seasonal influenza vaccine + MVA-NP+M1 + Sodium chloride	Influenza	Phase 2
MVA-NP+M1 + Saline + H3N2 (A/Belgium/2417/2015)	Influenza	Phase 2
ChAdOx1-MVA 5T4 vaccine + Nivolumab Infusion [Opdivo]	Intermediate Risk Prostate Cancer	Phase 1/2

Funding History

Total raised:$164M

IPO$75MUndisclosedOct 28, 2021

Series B$54MRA Capital ManagementFeb 15, 2021

Series A$35MGVApr 15, 2019

Opportunities

Barinthus targets large markets with high unmet need, including chronic hepatitis B (functional cure) and autoimmune diseases.

Positive early data for VTP-300 provides proof-of-concept and potential partnership value.

The dual-platform strategy offers multiple shots on goal across infectious and autoimmune diseases.

Risk Factors

The company faces significant clinical development risk with its early-stage pipeline, financial risk due to its pre-revenue status and need for near-term capital, and intense competition from larger, better-funded biopharma companies in its target indications.

Competitive Landscape

In hepatitis B, Barinthus competes with Gilead, Janssen, and others pursuing functional cures, differentiating with its antigen-specific immunotherapy approach. In autoimmunity, it faces emerging players like Anokion in the nascent field of antigen-specific tolerance. Its key strengths are platform versatility and strong academic validation.